Biological and clinical significance of HER2 overexpression in breast cancer

Breast Cancer

Volumn 8, Issue 1, 2001, Pages 45-51

  Kurebayashi, Junichi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Antibody; Biologic therapy; Breast cancer; HER2; Hsp90; Overexpression

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

BREAST TUMOR; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; PROGNOSIS; PROTO ONCOGENE; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0035220605     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967477     Document Type: Review

References (66)

1. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986. (Pubitemid 16128786)
2. Ullrich A, Coussens L, Hayrick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425, 1984. (Pubitemid 14102443)
3. Kraus MH, Issing W, Miki T, et al: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193-9197, 1989. (Pubitemid 20010391)
4. Plowman GD, Green JM, Culouscou JM, et al: Heregulin induces tyrosine phosphorylation of HER4˜ P180erbB4. Nature 366:473-475, 1993. (Pubitemid 24013882)
5. van der Geer P, Hunter T, Lindberg RA: Receptor protein- tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251-337, 1994. (Pubitemid 24372822)
6. Pelicci G, Lanfrancone L, Grignani F, et al: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93-104, 1992.
7. Lowenstein EJ, Daly RJ, Batzer AG, et al: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431-442, 1992.
8. Fedi P, Pierce JH, di Fiore PP, et al: Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 14:492-500, 1994.
9. Egan SE, Weinberg RA: The pathway to signal achievement. Nature 365:781-783, 1993. (Pubitemid 23341020)
10. Ming XF, Burgering BM, Wennstrom S, et al: Activation of p70/p85 S6 kinase by a pathway inaependent of p21ras. Nature 371:426-429, 1994.
11. Peles E, Levy RB, Or E, et al: Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J 10:2077-2086, 1991. (Pubitemid 21905679)
12. Savage CR Jr, Inagami T, Cohen S: The primary structure of epidermal growth factor. J Biol Chem 247:7612-7621, 1972.
13. Higashiyama S, Abraham JA, Miller J, et al: A heparinbinding growth factor secreted by macrophage-like cells that is related to EGF. Science 251:936-939, 1991. (Pubitemid 21926188)
14. Shing Y, Christofori G, Hanahan D, et al: Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259:1604-1607, 1993. (Pubitemid 23114638)
15. Peles E, Bacus SS, Koski RA, et al: Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216, 1992.
16. Goldman R, Levy RB, Peles E, et al: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29:11024-11028, 1990.
17. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997. (Pubitemid 27151960)
18. Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987. (Pubitemid 17095921)
19. Zhai YF, Beittenmiller H, Wang B, et al: Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 53:2272-2278, 1993. (Pubitemid 23156812)
20. Muller WJ, Sinn E, Pattengale PK, et al: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988.
21. Andrechek ER, Hardy WR, Siegel PM, et al: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 97:3444-3449, 2000. (Pubitemid 30183322)
22. Menard S, Tagliabue E, Campiglio M, et al: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182:150-162, 2000. (Pubitemid 30022667)
23. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996. (Pubitemid 26248546)
24. Sauter G, Feichter G, Torhorst J, et al: Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol40:164-173, 1996. (Pubitemid 26141465)
25. Busmanis I, Feleppa F, Jones A, et al: Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 26:261-267, 1994.
26. Roche PC, Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol17:434, 1999. (Pubitemid 29022424)
27. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
28. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol14:737-744, 1996.
29. J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998. (Pubitemid 28311914)
30. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998. (Pubitemid 28363029)
31. Slamon D, Leyland-Jones B, Shank S: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998.
32. Hoang MP, Sahin AA, Ordonez NG, et al: HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852-859, 2000. (Pubitemid 33051521)
33. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990. (Pubitemid 20032452)
34. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989. (Pubitemid 19106519)
35. Rosen PP, Lesser ML, Arroyo CD, et al: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75:1320-1326, 1995.
36. Bangalore L, Tanner AJ, Laudano AP, et al: Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. Proc Natl Acad Sci USA 89:11637-11641, 1992.
37. Bacus SS, Chin D, Yarden Y, et al: Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148:549-558, 1996. (Pubitemid 26056739)
38. Read LD, Keith D Jr, Slamon DJ, et al: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990. (Pubitemid 20225611)
39. Newman SP, Bates NP, Vernimmen D, et al: Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19:490-497, 2000. (Pubitemid 30099362)
40. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF- 7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993. (Pubitemid 23063891)
41. Tang CK, Perez C, Grunt T, et al: Involvement of heregulin-beta2 in the acquisition of the hormoneindependent phenotype of breast cancer cells. Cancer Res 56:3350-3358, 1996. (Pubitemid 26242988)
42. McCann AH, Dervan PA, O' Regan M, et al: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991.
43. Carlomagno C, Perrone F, Gallo C, et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996. (Pubitemid 26329655)
44. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992.
45. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol13:1129-1135, 1995.
46. Kunisue H, Kurebayashi J, Otsuki T, et al: Anti-HER2 antibody enhances the growth inhibitory effect of antioestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 82:46-51, 2000. (Pubitemid 30008957)
47. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
48. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998. (Pubitemid 28439959)
49. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
50. Jarvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. AmJPathol 156:839-847, 2000. (Pubitemid 30626942)
51. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.J Clin Oncol10:599-605, 1992.
52. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.J Clin Oncol 10:1049-1056, 1992.
53. Menard S, Valagussa P, Pilotti S, et al: HER2 overexpression and response to CMF in lymph node-positive breat cancer. Proc Am Soc Clin Oncol18:69a, 1999.
54. Baselga J, Seidman AD, Rosen PP, et al: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11 (Suppl 2) :43-48, 1997. (Pubitemid 27225846)
55. Disis ML, Cheever MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343-371, 1997.
56. Jinno H, Ueda M, Enomoto K, et al: Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Surg Today 26:501-507, 1996. (Pubitemid 126426347)
57. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to antip185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993. (Pubitemid 23300507)
58. Burstein H J, Kuter I, Richardson PG, et al: Hercepfin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study. Proc Am Soc Clin Oncol 19:102a, 2000.
59. Zhang L, Chang CJ, Bacus SS, et al: Suppressed transformation and induced differentiation of HER-2/neuoverexpressing breast cancer cells by emodin. Cancer Res 55:3890-3896, 1995.
60. Zhang L, Lau YK, Xia W, et al: Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neuoverexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin CancerRes 5:343-353, 1999. (Pubitemid 29085188)
61. Disis ML, Calenoff E, McLaughlin G, et al: Existent Tcell and antibody immunity to HER-2/neu protein in patients with breast cancer. CancerRes 54:16-20, 1994. (Pubitemid 24042079)
62. Disis ML, Pupa SM, Gralow JR, et al: High-titer HER- 2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363-3367, 1997. (Pubitemid 27485856)
63. Whitesell L, Mimnaugh EG, De Costa B, et al: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328, 1994.
64. Sharma SV, Agatsuma T, Nakano H: Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 16:2639-2645, 1998. (Pubitemid 28264041)
65. Kelland LR, Sharp SY, Rogers PM, et al: DTDiaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949, 1999.
66. Soga S, Neckers LM, Schulte TW, et al: KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hspg0 binding signaling molecules. Cancer Res 59:2931-2938, 1999. (Pubitemid 29283134)